Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005.
Identifieur interne : 003B54 ( Main/Exploration ); précédent : 003B53; suivant : 003B55Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005.
Auteurs : I G Barr [Australie] ; A C Hurt ; P. Iannello ; C. Tomasov ; N. Deed ; N. KomadinaSource :
- Antiviral research [ 0166-3542 ] ; 2007.
Descripteurs français
- KwdFr :
- Adamantane (pharmacologie), Antiviraux (pharmacologie), Australie (MeSH), Glycoprotéine hémagglutinine du virus influenza (génétique), Grippe humaine (virologie), Humains (MeSH), Mutation (MeSH), Oséltamivir (pharmacologie), Phylogenèse (MeSH), Rimantadine (pharmacologie), Résistance virale aux médicaments (MeSH), Sialidase (antagonistes et inhibiteurs), Virus de la grippe A (classification), Virus de la grippe A (effets des médicaments et des substances chimiques), Virus de la grippe A (génétique), Virus de la grippe A (isolement et purification), Zanamivir (pharmacologie).
- MESH :
- antagonistes et inhibiteurs : Sialidase.
- effets des médicaments et des substances chimiques : Virus de la grippe A.
- génétique : Glycoprotéine hémagglutinine du virus influenza, Virus de la grippe A.
- isolement et purification : Virus de la grippe A.
- pharmacologie : Adamantane, Antiviraux, Oséltamivir, Rimantadine, Zanamivir.
- virologie : Grippe humaine.
- Australie, Humains, Mutation, Phylogenèse, Résistance virale aux médicaments.
- Wicri :
- geographic : Australie.
English descriptors
- KwdEn :
- Adamantane (pharmacology), Antiviral Agents (pharmacology), Australia (MeSH), Drug Resistance, Viral (MeSH), Hemagglutinin Glycoproteins, Influenza Virus (genetics), Humans (MeSH), Influenza A virus (classification), Influenza A virus (drug effects), Influenza A virus (genetics), Influenza A virus (isolation & purification), Influenza, Human (virology), Mutation (MeSH), Neuraminidase (antagonists & inhibitors), Oseltamivir (pharmacology), Phylogeny (MeSH), Rimantadine (pharmacology), Zanamivir (pharmacology).
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , genetics : Hemagglutinin Glycoproteins, Influenza Virus.
- chemical , pharmacology : Adamantane, Antiviral Agents, Oseltamivir, Rimantadine, Zanamivir.
- geographic : Australia.
- classification : Influenza A virus.
- drug effects : Influenza A virus.
- genetics : Influenza A virus.
- isolation & purification : Influenza A virus.
- virology : Influenza, Human.
- Drug Resistance, Viral, Humans, Mutation, Phylogeny.
Abstract
The prevention and control of disease caused by seasonal and potential pandemic influenza viruses is currently managed by the use influenza vaccines and antivirals. The adamantanes (amantadine and rimantadine) were the first antivirals licensed for use against influenza A viruses and have been used extensively in some countries. Since the early 2000s increased resistance to these drugs has been reported especially in the A(H3) viruses. In this study we analysed recent human influenza A strains isolated in Australia and regionally for evidence of resistance to adamantanes and found evidence of significant resistant emerging during 2005.
DOI: 10.1016/j.antiviral.2006.08.002
PubMed: 16963130
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005.</title><author><name sortKey="Barr, I G" sort="Barr, I G" uniqKey="Barr I" first="I G" last="Barr">I G Barr</name><affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Melbourne 3052, Australia. Ian.Barr@influenzacenter.org</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Melbourne 3052</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Hurt, A C" sort="Hurt, A C" uniqKey="Hurt A" first="A C" last="Hurt">A C Hurt</name></author><author><name sortKey="Iannello, P" sort="Iannello, P" uniqKey="Iannello P" first="P" last="Iannello">P. Iannello</name></author><author><name sortKey="Tomasov, C" sort="Tomasov, C" uniqKey="Tomasov C" first="C" last="Tomasov">C. Tomasov</name></author><author><name sortKey="Deed, N" sort="Deed, N" uniqKey="Deed N" first="N" last="Deed">N. Deed</name></author><author><name sortKey="Komadina, N" sort="Komadina, N" uniqKey="Komadina N" first="N" last="Komadina">N. Komadina</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:16963130</idno><idno type="pmid">16963130</idno><idno type="doi">10.1016/j.antiviral.2006.08.002</idno><idno type="wicri:Area/Main/Corpus">003D34</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">003D34</idno><idno type="wicri:Area/Main/Curation">003D34</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">003D34</idno><idno type="wicri:Area/Main/Exploration">003D34</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005.</title><author><name sortKey="Barr, I G" sort="Barr, I G" uniqKey="Barr I" first="I G" last="Barr">I G Barr</name><affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Melbourne 3052, Australia. Ian.Barr@influenzacenter.org</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Melbourne 3052</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Hurt, A C" sort="Hurt, A C" uniqKey="Hurt A" first="A C" last="Hurt">A C Hurt</name></author><author><name sortKey="Iannello, P" sort="Iannello, P" uniqKey="Iannello P" first="P" last="Iannello">P. Iannello</name></author><author><name sortKey="Tomasov, C" sort="Tomasov, C" uniqKey="Tomasov C" first="C" last="Tomasov">C. Tomasov</name></author><author><name sortKey="Deed, N" sort="Deed, N" uniqKey="Deed N" first="N" last="Deed">N. Deed</name></author><author><name sortKey="Komadina, N" sort="Komadina, N" uniqKey="Komadina N" first="N" last="Komadina">N. Komadina</name></author></analytic><series><title level="j">Antiviral research</title><idno type="ISSN">0166-3542</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adamantane (pharmacology)</term><term>Antiviral Agents (pharmacology)</term><term>Australia (MeSH)</term><term>Drug Resistance, Viral (MeSH)</term><term>Hemagglutinin Glycoproteins, Influenza Virus (genetics)</term><term>Humans (MeSH)</term><term>Influenza A virus (classification)</term><term>Influenza A virus (drug effects)</term><term>Influenza A virus (genetics)</term><term>Influenza A virus (isolation & purification)</term><term>Influenza, Human (virology)</term><term>Mutation (MeSH)</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Oseltamivir (pharmacology)</term><term>Phylogeny (MeSH)</term><term>Rimantadine (pharmacology)</term><term>Zanamivir (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adamantane (pharmacologie)</term><term>Antiviraux (pharmacologie)</term><term>Australie (MeSH)</term><term>Glycoprotéine hémagglutinine du virus influenza (génétique)</term><term>Grippe humaine (virologie)</term><term>Humains (MeSH)</term><term>Mutation (MeSH)</term><term>Oséltamivir (pharmacologie)</term><term>Phylogenèse (MeSH)</term><term>Rimantadine (pharmacologie)</term><term>Résistance virale aux médicaments (MeSH)</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Virus de la grippe A (classification)</term><term>Virus de la grippe A (effets des médicaments et des substances chimiques)</term><term>Virus de la grippe A (génétique)</term><term>Virus de la grippe A (isolement et purification)</term><term>Zanamivir (pharmacologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adamantane</term><term>Antiviral Agents</term><term>Oseltamivir</term><term>Rimantadine</term><term>Zanamivir</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Australia</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéine hémagglutinine du virus influenza</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Adamantane</term><term>Antiviraux</term><term>Oséltamivir</term><term>Rimantadine</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Resistance, Viral</term><term>Humans</term><term>Mutation</term><term>Phylogeny</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Australie</term><term>Humains</term><term>Mutation</term><term>Phylogenèse</term><term>Résistance virale aux médicaments</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Australie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The prevention and control of disease caused by seasonal and potential pandemic influenza viruses is currently managed by the use influenza vaccines and antivirals. The adamantanes (amantadine and rimantadine) were the first antivirals licensed for use against influenza A viruses and have been used extensively in some countries. Since the early 2000s increased resistance to these drugs has been reported especially in the A(H3) viruses. In this study we analysed recent human influenza A strains isolated in Australia and regionally for evidence of resistance to adamantanes and found evidence of significant resistant emerging during 2005.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16963130</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0166-3542</ISSN><JournalIssue CitedMedium="Print"><Volume>73</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res</ISOAbbreviation></Journal><ArticleTitle>Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005.</ArticleTitle><Pagination><MedlinePgn>112-7</MedlinePgn></Pagination><Abstract><AbstractText>The prevention and control of disease caused by seasonal and potential pandemic influenza viruses is currently managed by the use influenza vaccines and antivirals. The adamantanes (amantadine and rimantadine) were the first antivirals licensed for use against influenza A viruses and have been used extensively in some countries. Since the early 2000s increased resistance to these drugs has been reported especially in the A(H3) viruses. In this study we analysed recent human influenza A strains isolated in Australia and regionally for evidence of resistance to adamantanes and found evidence of significant resistant emerging during 2005.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barr</LastName><ForeName>I G</ForeName><Initials>IG</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Melbourne 3052, Australia. Ian.Barr@influenzacenter.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurt</LastName><ForeName>A C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Iannello</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Tomasov</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Deed</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Komadina</LastName><ForeName>N</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0T2EF4JQTU</RegistryNumber><NameOfSubstance UI="D012299">Rimantadine</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6O3XI777I</RegistryNumber><NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>PJY633525U</RegistryNumber><NameOfSubstance UI="D000218">Adamantane</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000218" MajorTopicYN="N">Adamantane</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012299" MajorTopicYN="N">Rimantadine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>05</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>07</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>08</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16963130</ArticleId><ArticleId IdType="pii">S0166-3542(06)00256-7</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2006.08.002</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country><region><li>Victoria (État)</li></region><settlement><li>Melbourne</li></settlement></list><tree><noCountry><name sortKey="Deed, N" sort="Deed, N" uniqKey="Deed N" first="N" last="Deed">N. Deed</name><name sortKey="Hurt, A C" sort="Hurt, A C" uniqKey="Hurt A" first="A C" last="Hurt">A C Hurt</name><name sortKey="Iannello, P" sort="Iannello, P" uniqKey="Iannello P" first="P" last="Iannello">P. Iannello</name><name sortKey="Komadina, N" sort="Komadina, N" uniqKey="Komadina N" first="N" last="Komadina">N. Komadina</name><name sortKey="Tomasov, C" sort="Tomasov, C" uniqKey="Tomasov C" first="C" last="Tomasov">C. Tomasov</name></noCountry><country name="Australie"><region name="Victoria (État)"><name sortKey="Barr, I G" sort="Barr, I G" uniqKey="Barr I" first="I G" last="Barr">I G Barr</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B54 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B54 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16963130
|texte= Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16963130" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |